
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp has received a positive response from the market, as evidenced by a ~4% increase in share price, indicating investor optimism regarding the company's prospects. The firm is perceived as undervalued, trading at approximately 14 times net cash, with a favorable risk/reward profile anticipated over the next 12 to 24 months. Moreover, recent Phase 3 SAPPHIRE data bolsters confidence in potential regulatory approval and commercial viability, with management successfully addressing prior concerns related to their CDMO facility, signaling readiness for advancements in drug production.
Bears say
Scholar Rock Holding Corp faces a negative outlook primarily due to the delayed commercial launch of its lead asset, apitegromab, which has been pushed back significantly from the previously anticipated timeline. This delay not only lowers the company's peak sales estimates for apitegromab to $1.7 billion by 2035 but also introduces increased regulatory, competitive, and pricing risks that could impact its market position. The issuance of a Complete Response Letter (CRL) indicates unresolved issues that need addressing before a resubmission to the FDA, thereby contributing to uncertainty in the company’s revenue projections moving forward.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares